Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00229593 · ClinicalTrials.gov registry record · Phase 1
NES Gel-1, To Evaluate Nestorone Gel in Combination With Testosterone Gel
A Phase 1 study of Contraception, sponsored by University of Washington.
- Completed
- Registry status
- Phase 1
- Development phase
- 140
- Enrollment target
- 2
- Study locations
NCT00229593: Completed Phase 1 study of Contraception, sponsored by University of Washington.
NCT00229593 is a Phase 1 study of Contraception that has completed, run by University of Washington. The registered enrollment target is 140 participants, below the 453-participant average among 72 other Contraception trials with a reported enrollment target (69% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00229593, a Phase 1 study of Contraception, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 140 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to determine the usefulness of two transdermal gels to be used in the future development for a male contraceptive.
Conditions Studied
Interventions
- DRUG Nestorone gel
- DRUG Testosterone Gel
Study Locations (2)
California
- Harbor-UCLA Medical Center - Torrance
Washington
- University of Washington Medical Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2005-09 |
| Est. Completion | 2007-01 |
| Phase | Phase 1 |
What the finished NCT00229593 record still lists
NCT00229593 is an interventional study that assigns participants to a tested intervention. The registered 140 participants enrollment target is mid-sized for trials with a published cap, below the 453-participant average among 72 other Contraception trials with a reported enrollment target (69% lower).
The record links to 1 condition, with Contraception appearing as the primary indexed condition, and to 2 interventions - of which Nestorone gel is the first listed.
NCT00229593 reports a single indexed study location in California, Washington.
Frequently Asked Questions
What is clinical trial NCT00229593 about?
NCT00229593 is a clinical study titled "NES Gel-1, To Evaluate Nestorone Gel in Combination With Testosterone Gel". The purpose of this study is to determine the usefulness of two transdermal gels to be used in the future development for a male contraceptive.
What is the current status of trial NCT00229593?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 140 participants. The study started on 2005-09. Estimated completion is 2007-01.
What conditions does trial NCT00229593 study?
This clinical trial studies the following conditions: Contraception.
What interventions are being tested in trial NCT00229593?
The interventions under investigation include: Nestorone gel (DRUG), Testosterone Gel (DRUG).
Who is sponsoring clinical trial NCT00229593?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00229593 being conducted?
This trial has 2 study locations across California, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Contraception
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00229593's enrollment target sits among peer trials
140 38th of 72 higher than 35 of 72 other Contraception trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Contraception trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
ORAL T-6: Oral Androgens in Man-6
COMPLETED · Phase 1
-
Pharmacokinetic and Pharmacodynamic Study of Cyclofem
COMPLETED · Phase 1
-
Study to Evaluate Suppression of Ovulation and Pharmacokinetics of Medroxyprogesterone Acetate Following Administration of TV-46046 in Women With Ovulatory Cycle
COMPLETED · Phase 1
-
A Study to Evaluate the Pharmacokinetics (PK) of Medroxyprogesterone Acetate Following an Injection of TV-46046 in Healthy Women of Reproductive Age
COMPLETED · Phase 1
-
Oral Contraceptive Pill (OCP) Pharmacogenomics
RECRUITING · Phase 4
-
Intravenous Ketorolac Administration to Attenuate Post-procedural Pain Associated With Intrauterine Device Placement
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01419561 · 140 participants · Phase 2
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)
- NCT01624805 · 140 participants · Phase 2
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
- NCT02369770 · 140 participants · NA
Sensory-Motor Rehabilitation Post Stroke
- NCT02455193 · 140 participants · NA
Neuronal Effects of Exercise in Schizophrenia
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia